Prolonged Malignant Hyperthermia in the Absence of Triggering Agents

Schulte-Sasse U. , Hess W. , Eberlein H.J. Postoperative malignant hyperthermia and dantrolene therapy. Can Anaesth Soc J 1983; 30, 6: 635–640.

Souliere C. , Weintraub S. , Kirchner J.C. Markedly delayed postoperative malignant hyperthermia. Arch Otolaryngol Head Neck Surg 1986; 112: 564–566.

Kolb M. , Horne M. , Martz R. Dantrolene in human Malignant Hyperthermia. Anesthesiology 1982; 56: 254–262.

Grinberg R. , Edelist G. , Gordon A. Postoperative malignant hyperthermia in patients who received ‘safe’ anaesthetics. Can Anaesth Soc J 1983: 30, 3: 273–276.

Westlung K.J. , Fridrich K.L. , Warner D.S. , Sokoll M.D. An unusual anaesthetic course in a patient susceptible to malignant hyperthermia. J Oral Maxillofac Surg 1989; 47: 860–864.

King J.O. , Zapf A. A review of the value of creatine phosphokinase estimations in clinical medicine. Med J Aust 1972; 1: 699–703.

Britt B.A. The clinical aspects of Malignant Hyperthermia. In: Nalda Felipe M.A. , Gottman S. , Khambatta H.J. eds. Malignant Hyperthermia, Current Concepts. International course, Barcelona, Spain, Sept 15–17, 1988. Bad Homburg, Normad Vertag 1989; 91–107.

Merigan K.S. , Roberts J.R. Cocaine intoxication: Hyperpyrexia rhabdomyolysis and acute renal failure. Clin Toxicol 1987; 25: 135–148.

Fletcher R. , Blennow G. , Olsson A.K. , Ranklev E. , Tornebrandt K. Malignant hyperthermia in a myopathic child. Prolonged postoperative course requiring dantrolene. Acta Anaesthiol Scand 1982; 26: 435–438.

Waite P.D. , Ballard J.B. , Yonfa A. Malignant hyperthermia in a patient receiving nitrous oxide. J Oral Maxillofac Surg 1985; 43: 907–909.

Gronert G.A. , Milde J.H. Hyperbaric nitrous oxide and malignant hyperthermia. Br J Anaesth 1981; 53: 1238.

Britt B.A. Combined anaesthetic and stress induced malignant hyperthermia in two offspring of malignant hyperthermia susceptible parents. Anesth Analg 1988; 67: 393–399.

Ellis F.R. , Green J.H. , Campbell I.T. Muscle activity, pH, and malignant hyperthermia. Br J Anaesth 1991; Vol 66, 5: 535–537.

Gronert G.A. Malignant Hyperthermia. In: Engel A.G. , Banker B.Q. eds. Myology, McGraw Hill, 1986; 1763–1784.

Gronert G. , Thompson R. , Onofrio B. Human Malignant Hyperthermia: awake episodes and correction by dantrolene. Anesth Analg 1980; 59, 5: 377–378.

Wingard D.W. , Gatz E.E. Some observations in stress susceptible patients. In: Aldrete J.A. , Britt B.A. eds. Second International Symposium on Malignant Hyperthermia. New York, Grune Stratton 1978; 363–372.

Denborough M. Malignant hyperpyrexia, heatstroke, and sudden infant death. Fellowship Affairs; October 1990; 13–14, 27.

Kemp D.R. , Choong L.S. Malignant Hyperthermia and the conscious patient. Aust NZ J Surg 1988; 58: 423–427.

Feuerman T. , Gade G.F. , Reynolds R. Stress-induced malignant hyperthermia in a head-injured patient. J Neurosurg 1988; 68: 297–299.

Britt B.A. Malignant Hyperthermia. Can Anaesth Soc J 1985; 32, 6: 666–677.

Hein H.A. , Jantzen J.A. , Roewer M. Sudden death: Is there a human stress syndrome? JAMA 1987; 257, 10: 1328.

Allsop P. , Jorfieldt L. , Rutberg H. , Lennmarken C. , Hall G.M. Delayed recovery of muscle pH after short duration, high intensity exercise in malignant hyperthermia susceptible subjects. Br J Anaesth 1991; 66, 5: 541–545.

Hackl W. , Winkler M. , Mauritz W. Relationship between exercise induced myolysis and malignant hyperthermia. Br J Anaesth 1991; 67: 221.

Hackl W. , Mauritz W. , Winkler M. , Sporn P. , Steinweither K. Anaesthesia in malignant hyperthermia susceptible patients without dantrolene prophylaxis: a report of 30 cases. Acta Anaesthesiol Scand 1990; 34: 534–537.

Watson C.B. , Reierson N. , Norfleet E. Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology 1986; 65: 312–314.

Flewellen E.H. , Nelson T.E. Dantrolene dose response in awake man. Implications for management of malignant hyperthermia. Anesthesiology 1983; 59: 275–280.

Allen G.C. , Cattran B.C. , Peterson R.G. , Lalande M. Plasma levels of Dantrolene following oral administration in Malignant Hyperthermia susceptible Patients. Anesthesiology 1988; 69: 900–904.

Cunliffe M. , Lerman J. , Britt B.A. Is prophylactic dantrolene indicated for MHS patients undergoing elective surgery? Anesth Analg 1987; 66: S35.

Ruhland G. , Hinkle A.J. Malignant hyperthermia after oral and intravenous treatment with dantrolene in a patient susceptible to malignant hyperthermia. Anesthesiology 1984; 60: 159–160.

Mora C.T. , Eisenkraft J.B. Dantrolene prophylaxis and neuromuscular disorders. Anesthesiology 1987; 66: 702.